PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway - PubMed
3 hours ago
- #ERK/p38 MAPK pathway
- #PCSK9 inhibitor
- #Diabetic cardiomyopathy
- PCSK9 inhibitor alirocumab improves diabetic cardiomyopathy.
- Alirocumab enhances cell viability and reduces oxidative stress in H9c2 cells under high glucose stress.
- The inhibitor decreases inflammatory reaction and mitochondrial apoptosis-related proteins.
- In vivo, alirocumab reduces myocardial hypertrophy and improves cardiac function in diabetic mice.
- Alirocumab increases mitochondrial size and quantity, promoting fusion and reducing damaged mitochondria.
- It reduces myocardial fibrosis and oxidative stress in mice.
- The protective effects are mediated through the ERK/p38 MAPK pathway.
- Study provides experimental support for clinical application of alirocumab in diabetic cardiomyopathy.